Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

Firebrick Pharma Limited (FRE.AX)

Compare
0.0870
0.0000
(0.00%)
At close: April 4 at 4:10:37 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Executive Chairman & CEO 296.14k -- 1954
Dr. Stephen Francis Goodall MASc, MBA Founder, COO & Executive Director 250.09k -- --
Mr. Kavi Bekarma B.Sc., C.A. Chief Financial Officer -- -- --
Dr. Simon Tucker Chief Scientific Officer -- -- --
Prof. Peter Friedland Chief Medical Officer -- -- --
Dr. Monique Baldwin Head of Regulatory Affairs -- -- --
Mr. Stephen Buckley Company Secretary -- -- --

Firebrick Pharma Limited

440 Collins Street
Level 10
Melbourne, VIC 3000
Australia
1300 301 874 https://www.firebrickpharma.com
Sector: 
Healthcare

Description

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

Corporate Governance

Firebrick Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events